At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Colesevelam HCl +1 moredrug
Likely dose
Colesevelam HCl 3.75 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Co-administration of Colesevelam and Sitagliptin on Glucose Metabolism in Patients With Type 2 Diabetes
In Brief
A clinical study evaluating Colesevelam HCl and Sitagliptin for Diabetes Mellitus, Type 2. Completed, enrolled 61 participants across 3 sites.
Detailed Summary
This study will assess the effects of colesevelam, alone or in combination with sitagliptin, on glucose metabolism in subjects with T2DM inadequately controlled by diet and exercise
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMar 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedMar 25, 2010
Enrollment StartMar 1, 2010
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.3 years ago
Interventions
Colesevelam HCldrug
Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Sitagliptindrug
Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.